Crispens Marta A, Bodurka Diane, Deavers Michael, Lu Karen, Silva Elvio G, Gershenson David M
Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9640, USA.
Obstet Gynecol. 2002 Jan;99(1):3-10. doi: 10.1016/s0029-7844(01)01649-0.
To evaluate the response to therapy and survival of patients with progressive or recurrent serous ovarian tumors of low malignant potential.
Fifty-three patients with progressive or recurrent serous ovarian tumors of low malignant potential were identified. Response was assessed and progression-free and overall survival were analyzed. The influence of clinicopathologic factors on survival was determined.
In 49 patients with known histology of progression or recurrence, 36 (73%) had low-grade serous carcinoma, and 13 (27%) had serous ovarian tumors of low malignant potential. Forty-five patients received nonsurgical therapy and had an evaluable response. There were six (13%) patients with a complete response and six (13%) patients with a partial response. The median time to first progression or recurrence was 5.6 years. Median survival from diagnosis of first recurrence was 7.7 years. Median survival from initial diagnosis was 21 years. Nineteen (36%) patients are dead of tumor. Patients who recurred with low-grade serous carcinoma were more likely to die of tumor than those with serous ovarian tumors of low malignant potential (47% versus 0%, P =.045). Optimal cytoreduction was associated with improved survival (P =.007).
Patients with progressive or recurrent serous ovarian tumors of low malignant potential have a long interval from diagnosis to progression and from progression to death, resulting in extended overall survival. Recurrence as low-grade serous carcinoma and failure to achieve optimal secondary cytoreduction were adverse prognostic factors. There were few responses to nonsurgical therapy.
评估低恶性潜能的浆液性卵巢肿瘤进展期或复发患者的治疗反应及生存情况。
确定53例低恶性潜能的浆液性卵巢肿瘤进展期或复发患者。评估治疗反应，并分析无进展生存期和总生存期。确定临床病理因素对生存的影响。
在49例已知进展或复发组织学的患者中，36例（73%）为低级别浆液性癌，13例（27%）为低恶性潜能的浆液性卵巢肿瘤。45例患者接受了非手术治疗并具有可评估的反应。有6例（13%）患者完全缓解，6例（13%）患者部分缓解。首次进展或复发的中位时间为5.6年。从首次复发诊断开始的中位生存期为7.7年。从初始诊断开始的中位生存期为21年。19例（36%）患者死于肿瘤。低级别浆液性癌复发的患者比低恶性潜能的浆液性卵巢肿瘤患者更易死于肿瘤（47%对0%，P = 0.045）。最佳细胞减灭术与生存期改善相关（P = 0.007）。
低恶性潜能的浆液性卵巢肿瘤进展期或复发患者从诊断到进展以及从进展到死亡的间隔时间较长，从而导致总生存期延长。复发为低级别浆液性癌以及未能实现最佳的二次细胞减灭术是不良预后因素。非手术治疗的反应较少。
